Загрузка...

Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life

OBJECTIVE: The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)]. METHODS: This was a pr...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Intern Med
Главные авторы: Kawakubo, Megumi, Eguchi, Yuichiro, Okada, Michiaki, Iwane, Shinji, Oeda, Satoshi, Otsuka, Taiga, Nakashita, Syunya, Araki, Norimasa, Koga, Akemi
Формат: Artigo
Язык:Inglês
Опубликовано: The Japanese Society of Internal Medicine 2018
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6096027/
https://ncbi.nlm.nih.gov/pubmed/29526929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0091-17
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!